dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Beer, M. | en |
dc.contributor.author | Makrantonakis, P. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Pantelakos, P. | en |
dc.contributor.author | Tsavaris, N. | en |
dc.contributor.author | Karpasitis, N. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Beer, M. | en |
dc.creator | Makrantonakis, P. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Pantelakos, P. | en |
dc.creator | Tsavaris, N. | en |
dc.creator | Karpasitis, N. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.date.accessioned | 2018-06-22T09:53:15Z | |
dc.date.available | 2018-06-22T09:53:15Z | |
dc.date.issued | 1993 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41740 | |
dc.description.abstract | Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks or longer, 38 experienced weight gain. Monthly subjective evaluation of six parameters using a linear analog self-assessment (LASA) form showed a significant improvement in the patient's rating of appetite, mood, nausea and vomiting, and quality of life; the tumor was progressive in 21, stable in 11 and it regressed in only 9 of these patients. No toxicity was observed; one case of death due to a congestive heart failure remains unexplained. MA at the dose used is a powerful appetite stimulant; it contributes to weight increase and might improve the subjective appreciation of quality of life. MA at lower doses should be compared in a prospective trial to the dose used in this study. ©1993 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted. | en |
dc.language.iso | eng | en |
dc.source | Acta Oncologica | en |
dc.subject | Article | en |
dc.subject | Cancer | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Priority journal | en |
dc.subject | Anorexia | en |
dc.subject | Male | en |
dc.subject | Quality of life | en |
dc.subject | Weight reduction | en |
dc.subject | Pilot projects | en |
dc.subject | Oral drug administration | en |
dc.subject | Middle age | en |
dc.subject | Weight loss | en |
dc.subject | Megestrol acetate | en |
dc.subject | Non-u.s. gov't | en |
dc.subject | Support | en |
dc.subject | Megestrol | en |
dc.title | Megestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.3109/02841869309083883 | |
dc.description.volume | 32 | |
dc.description.issue | 1 | |
dc.description.startingpage | 37 | |
dc.description.endingpage | 41 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |